Blog
RSS FeedPosted by Michael Wonder on 05 Feb 2025
Medexus and Ontario's Provincial Health Services successfully complete agreements for public reimbursement of Trecondyv (treosulfan for injection) in Ontario, Canada
4 February 2025 - Medexus recently completed listing agreements with Ontario's Ministry of Health (Ontario Public Drug Programs) and Ontario ...
Posted by Michael Wonder on 03 Feb 2025
Proposal to fund a new oral contraceptive pill
3 February 2025 - PHARMAC is consulting on funding a new progestogen-only oral contraceptive pill called desogestrel (Cerazette) from 1 ...
Posted by Michael Wonder on 02 Feb 2025
Life-saving lung cancer drug added to PBS, slashing price from $10,000 a month to $30 per script
1 February 2025 - Australians diagnosed with a rare form of lung cancer will now have access to a life-saving ...
Posted by Michael Wonder on 02 Feb 2025
Cheaper medicine for lung cancer patients
2 February 2025 - The Australian Government is listing Retevmo (selpercatinib) on the PBS for the first time to treat advanced ...
Posted by Michael Wonder on 02 Feb 2025
Cell and gene therapies - improving access and outcomes for Medicare and Medicaid beneficiaries
1 February 2025 - State Medicaid agencies can now apply to participate in a new model that supports voluntary, outcomes-based agreements ...
Posted by Michael Wonder on 01 Feb 2025
Groundbreaking one-off gene therapy approved for severe sickle cell disease
31 January 2025 - People in England with severe sickle cell disease will be among the first to receive treatment using ...
Posted by Michael Wonder on 01 Feb 2025
Schedule of Pharmaceutical Benefits - 1 February 2025
1 February 2025 - The February 2025 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 01 Feb 2025
New Zealand Pharmaceutical Schedule - 1 February 2025
1 February 2025 - The February 2025 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 01 Feb 2025
Boehringer Ingelheim’s Jardiance gets expanded coverage for HFpEF patients
31 January 2025 - Boehringer Ingelheim Korea said that Jardiance (empagliflozin) 10 mg tablet, its sodium-glucose co-transporter-2 inhibitor, received expanded ...
Posted by Michael Wonder on 31 Jan 2025
Vertex announces Casgevy reimbursement agreement for the treatment of sickle cell disease in England
31 January 2025 - Agreement means eligible sickle cell disease patients in England now have access to Casgevy. ...
Posted by Michael Wonder on 29 Jan 2025
Von Hippel-Lindau disease drug Welireg listed on PBS slashing cost by $11,000 a month for patients
28 January 2025 - The treatment for Simon Goodrich’s disease has been costing $12,000 a month, but there has been a ...
Posted by Michael Wonder on 28 Jan 2025
Drugs for rare diseases – Ontario agreement
24 January 2025 - Today, the Governments of Canada and the province of Ontario signed the National Strategy for Drugs ...
Posted by Michael Wonder on 21 Jan 2025
Immunotherapy Qarziba to be reimbursed for high-risk neuroblastoma patients starting next month
28 November 2024 - The treatment landscape for neuroblastoma, the most common cancer in children outside of blood and brain ...
Posted by Michael Wonder on 19 Jan 2025
Protection against RSV for mums and bubs with free vaccine available from 3 February
19 January 2025 - From 3 February 2025, Australian mums and their newborn babies will have free access to the best ...
Posted by Michael Wonder on 16 Jan 2025
PHARMAC consulting on widening access to venetoclax, azacitidine and upadacitinib monohydrate
16 January 2025 - PHARMAC is asking for feedback on a proposal to widen access to three medicines for five ...